Mechanism of Action: Lesuride vs Pruvict
There appears to be confusion in your question: "Lesuride" (levosulpiride) and "Pruvict" (prucalopride) are two entirely different medications with distinct mechanisms of action, not variations of the same drug.
Levosulpiride (Lesuride)
Levosulpiride operates through a dual mechanism: it acts as both a D2 dopamine receptor antagonist AND a serotonin 5-HT4 receptor agonist 1, 2. This combination gives it both prokinetic and antiemetic properties.
Specific Mechanisms:
- D2 Dopamine Receptor Blockade: Preferentially blocks presynaptic D2 receptors in dopaminergic pathways, functioning as a selective autoreceptor blocker 3
- 5-HT4 Receptor Agonism: Acts as a moderate agonist at 5-HT4 receptors, conferring cholinergic effects 2
- Net Effect: Facilitates acetylcholine release from enteric motor neurons, particularly in the gastric antrum and jejunum 4
Clinical Actions:
- Accelerates gastric and gallbladder emptying at 25mg three times daily 1
- Increases EFS-induced cholinergic contractions in gastric antrum (+37%) and jejunum (+45%) 4
- Provides both prokinetic AND direct antiemetic effects through D2 blockade
Prucalopride (Pruvict)
Prucalopride functions purely as a selective 5-HT4 receptor agonist with NO dopamine receptor activity 5.
Specific Mechanisms:
- Selective 5-HT4 Agonism: Highly selective serotonin 5-HT4 receptor agonist
- No Antiemetic Properties: The mechanism is purely prokinetic without any direct antiemetic effects 5
- No D2 Activity: Does not block dopamine receptors
Clinical Actions:
- Established efficacy for chronic idiopathic constipation (CIC)
- May benefit gastroparesis, particularly idiopathic cases
- Less effective in diabetes or connective tissue disease-related gastroparesis 5
Key Differences
| Feature | Levosulpiride | Prucalopride |
|---|---|---|
| Primary Mechanism | D2 antagonist + 5-HT4 agonist | Pure 5-HT4 agonist |
| Antiemetic Effect | Yes (via D2 blockade) | No |
| Prokinetic Effect | Yes (dual mechanism) | Yes (single mechanism) |
| Movement Disorder Risk | HIGH - causes parkinsonism, dystonia, tremor [6,7,8] | Minimal |
| Prolactin Elevation | Yes (major drawback) [9] | No |
Critical Safety Distinction
The most important clinical difference is the extrapyramidal side effect profile:
Levosulpiride: Significant risk of parkinsonism, acute dystonia, tremor, and stiffness due to D2 blockade 7, 8. A prospective study found statistically significant correlation (r=0.8295, P=0.0154) between treatment duration and tremor/stiffness incidence 8
Prucalopride: Monitor for depression and suicidal ideation (small risk), but no extrapyramidal effects 5
Common Pitfall:
Levosulpiride-induced parkinsonism is frequently under-recognized in clinical practice 8. Always consider recent levosulpiride use when evaluating new-onset extrapyramidal symptoms, particularly in elderly patients (average age 65 years in one series) 8. Complete remission typically occurs within 2.5 months after discontinuation 7.